For upcoming studies, it would be important to identify any potential high-risk subgroups as well as assess whether the elevated risk of NAION is a drug class effect or a specific finding for subcutaneously administered semaglutide. 12.02.24 MDL cases continued to grow in December The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,300
For how GLP-1 affected my actual race performances, see my race results with data
Comparing Numbers Only What people expect: This drug gives 15% weight loss, that one gives 10%so the first is better. What actually matters: Numbers dont show the daily experience
Dall'Asen tested the brighter red hue, Boasty, and enjoyed the comfortable, customizable formula
You should have him see a functional doc who can order more comprehensive testing to determine the cause, such as organic acids and stool profile